Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma

References

• Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009:523–531.
   PubMedGoogle Scholar
• Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007;110:2259–2267.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11–23.
   PubMed Web of Science ®Google Scholar
• Kawauchi K, Ogasawara T, Yasuyama M, et al. The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem 2009;9:550–559.
   PubMed Web of Science ®Google Scholar
• Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008;18: 254–267.
   PubMed Web of Science ®Google Scholar
• Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003;101:4667–4679.
   PubMed Web of Science ®Google Scholar
• Lai R, Ingham RJ. The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update. Ther Adv Hematol 2013;4:119–131.
   PubMedGoogle Scholar
• Staber PB, Vesely P, Haq N, et al. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood 2007;110:3374–3383.
   PubMed Web of Science ®Google Scholar
• Bai RY, Ouyang T, Miething C, et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000;96:4319–4327.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Simmons WJ, Cai H, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005;11:623–629.
   PubMed Web of Science ®Google Scholar
• Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 2000;19:2607–2611.
   PubMed Web of Science ®Google Scholar
• Calo V, Migliavacca M, Bazan V, et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 2003;197:157–168.
   PubMed Web of Science ®Google Scholar
• Dauer DJ, Ferraro B, Song L, et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005;24:3397–3408.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Sasaki M, Itoh K, et al. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res 2005;65:7628–7634.
   PubMed Web of Science ®Google Scholar
• Shaulian E. AP-1--The Jun proteins: oncogenes or tumor suppressors in disguise? Cell Signal 2010;22:894–899.
   PubMed Web of Science ®Google Scholar
• Haddad Y, Vallerand D, Brault A, et al. Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid Based Complement Alternat Med 2011; 2011:nep164.
   Google Scholar
• Serviddio G, Bellanti F, Stanca E, et al. Silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis. Free Radic Biol Med 2014;73:117–126.
   PubMed Web of Science ®Google Scholar
• Wu JW, Lin LC, Hung SC, et al. Hepatobiliary excretion of silibinin in normal and liver cirrhotic rats. Drug Metab Dispos 2008;36:589–596.
   PubMed Web of Science ®Google Scholar
• Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006;124:491–504.
   PubMed Web of Science ®Google Scholar
• Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis 1999;20:2101–2108.
   PubMed Web of Science ®Google Scholar
• Cheung CW, Gibbons N, Johnson DW, et al. Silibinin—a promising new treatment for cancer. Anticancer Agents Med Chem 2010;10:186–195.
   PubMed Web of Science ®Google Scholar
• Tyagi A, Singh RP, Ramasamy K, et al. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res (Phila) 2009;2:74–83.
   PubMed Web of Science ®Google Scholar
• Dastpeyman M, Motamed N, Azadmanesh K, et al. Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of beta1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI. Med Oncol 2012;29:2512–2518.
   PubMed Web of Science ®Google Scholar
• Kauntz H, Bousserouel S, Gosse F, et al. Silibinin, a natural flavonoid, modulates the early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis. Int J Oncol 2012;41:849–854.
   PubMed Web of Science ®Google Scholar
• Kaur M, Velmurugan B, Tyagi A, et al. Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling. Neoplasia 2010;12:415–424.
   PubMed Web of Science ®Google Scholar
• Varghese L, Agarwal C, Tyagi A, et al. Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res 2005;11:8441–8448.
   PubMed Web of Science ®Google Scholar
• Lee MH, Huang Z, Kim DJ, et al. Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth. Cancer Prev Res (Phila) 2013;6:455–465.
   PubMed Web of Science ®Google Scholar
• Singh RP, Tyagi A, Sharma G, et al. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin Cancer Res 2008;14:300–308.
   PubMed Web of Science ®Google Scholar
• Deep G, Gangar SC, Rajamanickam S, et al. Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling. PLoS One 2012;7:e34630.
   Google Scholar
• Liang L, Li L, Zeng J, et al. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway. Oncol Rep 2012;28:999–1005.
   PubMed Web of Science ®Google Scholar
• Agarwal C, Tyagi A, Kaur M, et al. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 2007;28:1463–1470.
   PubMed Web of Science ®Google Scholar
• Kim S, Jeon M, Lee J, et al. Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells. Oncol Rep 2014;32:2230–2236
   PubMed Web of Science ®Google Scholar
• Wang YX, Cai H, Jiang G, et al. Silibinin inhibits proliferation, induces apoptosis and causes cell cycle arrest in human gastric cancer MGC803 cells via stat3 pathway inhibition. Asian Pac J Cancer Prev 2014;15:6791–6798.
   PubMed Web of Science ®Google Scholar
• Gelebart P, Hegazy SA, Wang P, et al. Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma. Blood Cancer J 2012;2:e82.
   PubMed Web of Science ®Google Scholar
• Buttke TM, McCubrey JA, Owen TC. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J Immunol Methods 1993;157:233–240.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
   PubMed Web of Science ®Google Scholar
• Molavi O, Wang P, Zak Z, et al. Gene methylation and silencing of SOCS3 in mantle cell lymphoma. Br J Haematol 2013;161:348–356.
   PubMed Web of Science ®Google Scholar
• Samadi N, Gaetano C, Goping IS, et al. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 2009;28:1028–1039.
   PubMed Web of Science ®Google Scholar
• Colomba A, Giuriato S, Dejean E, et al. Inhibition of Rac controls NPM-ALK-dependent lymphoma development and dissemination. Blood Cancer J 2011;1:e21.
   Google Scholar
• Crockett DK, Lin Z, Elenitoba-Johnson KS, et al. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 2004;23:2617–2629.
   PubMed Web of Science ®Google Scholar
• Pearson JD, Lee JK, Bacani JT, et al. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma. Int J Clin Exp Pathol 2011;4:124–133.
   PubMed Web of Science ®Google Scholar
• Piva R, Pellegrino E, Mattioli M, et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 2006;116:3171–3182.
   PubMed Web of Science ®Google Scholar
• Raina K, Agarwal R. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms. Acta Pharmacol Sin 2007;28:1466–1475.
   PubMed Web of Science ®Google Scholar
• Inghirami G, Pileri SA. Anaplastic large-cell lymphoma. Semin Diagn Pathol 2011;28:190–201.
   PubMed Web of Science ®Google Scholar
• Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997;14:439–449.
   PubMed Web of Science ®Google Scholar
• Amin HM, McDonnell TJ, Ma Y, et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 2004;23:5426–5434.
   PubMed Web of Science ®Google Scholar
• Gough DJ, Koetz L, Levy DE. The MEK-ERK pathway is necessary for serine phosphorylation of mitochondrial STAT3 and Ras-mediated transformation. PLoS One 2013;8:e83395.
   PubMed Web of Science ®Google Scholar
• O’Connor ML, Xiang D, Shigdar S, et al. Cancer stem cells: a contentious hypothesis now moving forward. Cancer Lett 2014;344: 180–187.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007;25:139–146.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Glode M, Gustafson D, et al. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010;70:848–855.
   PubMed Web of Science ®Google Scholar
• Mulrow C, Lawrence V, Jacobs B, et al. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Evid Rep Technol Assess (Summ) 2000;21:1–3.
   PubMedGoogle Scholar
• Ting H, Deep G, Agarwal R. Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J 2013;15:707–716.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ge Y, Chen Y, et al. Cellular and molecular mechanisms of silibinin induces cell-cycle arrest and apoptosis on HeLa cells. Cell Biochem Funct 2012;30:243–248.
   PubMed Web of Science ®Google Scholar
• Hoh C, Boocock D, Marczylo T, et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res 2006;12:2944–2950.
   PubMed Web of Science ®Google Scholar
• Wu K, Ning Z, Zeng J, et al. Silibinin inhibits beta-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. Cell Signal 2013;25:2625–2633.
   PubMed Web of Science ®Google Scholar
• Singh RP, Raina K, Sharma G, et al. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial–mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 2008;14:7773–7780.
   PubMed Web of Science ®Google Scholar
• Raina K, Rajamanickam S, Singh RP, et al. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008;68:6822–6830.
   PubMed Web of Science ®Google Scholar
• Xu P, Yin Q, Shen J, et al. Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS. Int J Pharm 2013;454:21–30.
   PubMed Web of Science ®Google Scholar
• Turner SD, Alexander DR. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? Leukemia 2005; 19:1128–1134.
   PubMed Web of Science ®Google Scholar